


## AC1Q3QWB

Cat. No.:	HY-161024		
CAS No.:	46697-00-1		
Molecular Formula:	C <sub>12</sub> H <sub>15</sub> Cl <sub>2</sub> NO		
Molecular Weight:	260.16		
Target:	Histone Methyltransferase		
Pathway:	Epigenetics		
Storage:	Pure form	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (384.38 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.8438 mL	19.2189 mL	38.4379 mL
	5 mM		0.7688 mL	3.8438 mL	7.6876 mL
	10 mM		0.3844 mL	1.9219 mL	3.8438 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (9.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (9.61 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (9.61 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of Tazemetostat in endometrial cancer<sup>[1]</sup>.

### REFERENCES

---

[1]. Lingli Chen, et al. Compound AC1Q3QWB upregulates CDKN1A and SOX17 by interrupting the HOTAIR-EZH2 interaction and enhances the efficacy of tazemetostat in endometrial cancer. *Cancer Lett.* 2023 Dec 1:578:216445.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA